289 related articles for article (PubMed ID: 21640633)
1. Translational imaging endpoints to predict treatment response to novel targeted anticancer agents.
Serkova NJ
Drug Resist Updat; 2011; 14(4-5):224-35. PubMed ID: 21640633
[TBL] [Abstract][Full Text] [Related]
2. Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents.
Serkova NJ; Eckhardt SG
Front Oncol; 2016; 6():152. PubMed ID: 27471678
[TBL] [Abstract][Full Text] [Related]
3. The role of functional imaging in the era of targeted therapy of renal cell carcinoma.
Braunagel M; Graser A; Reiser M; Notohamiprodjo M
World J Urol; 2014 Feb; 32(1):47-58. PubMed ID: 23588813
[TBL] [Abstract][Full Text] [Related]
4. Oncologic imaging end-points for the assessment of therapy response.
Serkova NJ; Garg K; Bradshaw-Pierce EL
Recent Pat Anticancer Drug Discov; 2009 Jan; 4(1):36-53. PubMed ID: 19149687
[TBL] [Abstract][Full Text] [Related]
5. Novel oncologic drugs: what they do and how they affect images.
Figueiras RG; Padhani AR; Goh VJ; Vilanova JC; González SB; Martín CV; Caamaño AG; Naveira AB; Choyke PL
Radiographics; 2011; 31(7):2059-91. PubMed ID: 22084189
[TBL] [Abstract][Full Text] [Related]
6. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
[TBL] [Abstract][Full Text] [Related]
7. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
[TBL] [Abstract][Full Text] [Related]
8. Radiological evaluation of response to treatment: application to metastatic renal cancers receiving anti-angiogenic treatment.
Ammari S; Thiam R; Cuenod CA; Oudard S; Hernigou A; Grataloup C; Siauve N; Medioni J; Fournier LS
Diagn Interv Imaging; 2014 Jun; 95(6):527-39. PubMed ID: 24906810
[TBL] [Abstract][Full Text] [Related]
9. Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy.
Padhani AR; Khan AA
Target Oncol; 2010 Mar; 5(1):39-52. PubMed ID: 20383784
[TBL] [Abstract][Full Text] [Related]
10. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
Frampas E; Lassau N; Zappa M; Vullierme MP; Koscielny S; Vilgrain V
Eur J Radiol; 2013 May; 82(5):e205-11. PubMed ID: 23273822
[TBL] [Abstract][Full Text] [Related]
11. Non-invasive imaging for studying anti-angiogenic therapy effects.
Ehling J; Lammers T; Kiessling F
Thromb Haemost; 2013 Mar; 109(3):375-90. PubMed ID: 23407722
[TBL] [Abstract][Full Text] [Related]
12. Prognostication and response assessment in liver and pancreatic tumors: The new imaging.
De Robertis R; Tinazzi Martini P; Demozzi E; Puntel G; Ortolani S; Cingarlini S; Ruzzenente A; Guglielmi A; Tortora G; Bassi C; Pederzoli P; D'Onofrio M
World J Gastroenterol; 2015 Jun; 21(22):6794-808. PubMed ID: 26078555
[TBL] [Abstract][Full Text] [Related]
13. QA procedures for multimodality preclinical tumor drug response testing.
Lee YC; Goins BA; Fullerton GD
Med Phys; 2010 Sep; 37(9):4806-16. PubMed ID: 20964200
[TBL] [Abstract][Full Text] [Related]
14. Treatment Response Evaluation of Breast Cancer after Neoadjuvant Chemotherapy and Usefulness of the Imaging Parameters of MRI and PET/CT.
An YY; Kim SH; Kang BJ; Lee AW
J Korean Med Sci; 2015 Jun; 30(6):808-15. PubMed ID: 26028936
[TBL] [Abstract][Full Text] [Related]
15. [Targeted treatments: which imaging?].
Lassau N; Chebil M; Benatsou B; Chami L; Roche A
Bull Cancer; 2008 Oct; 95(10):989-93. PubMed ID: 19004731
[TBL] [Abstract][Full Text] [Related]
16. Imaging in the age of molecular medicine: monitoring of anti-angiogenic treatments.
Lederle W; Palmowski M; Kiessling F
Curr Pharm Biotechnol; 2012 Mar; 13(4):595-608. PubMed ID: 22214504
[TBL] [Abstract][Full Text] [Related]
17. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis.
Bäuerle T; Bartling S; Berger M; Schmitt-Gräff A; Hilbig H; Kauczor HU; Delorme S; Kiessling F
Eur J Radiol; 2010 Feb; 73(2):280-7. PubMed ID: 19070445
[TBL] [Abstract][Full Text] [Related]
18. The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis.
Drevs J; Schneider V
J Intern Med; 2006 Dec; 260(6):517-29. PubMed ID: 17116002
[TBL] [Abstract][Full Text] [Related]
19. Dynamic contrast-enhanced MRI in oncology drug development.
Cheng HL
Curr Clin Pharmacol; 2007 May; 2(2):111-22. PubMed ID: 18690858
[TBL] [Abstract][Full Text] [Related]
20. Dynamic contrast-enhanced magnetic resonance imaging and blood oxygenation level-dependent magnetic resonance imaging for the assessment of changes in tumor biology with treatment.
Li SP; Padhani AR; Makris A
J Natl Cancer Inst Monogr; 2011; 2011(43):103-7. PubMed ID: 22043053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
